Abstract
In the context of an ongoing pandemic of the COVID-19, most experts have noticed that the SARS-CoV-2 enters cells through the angiotensin-converting enzyme 2 protein, which plays an important role in the renin-angiotensin-aldosterone system. This, together with the finding that the COVID-19 disease is more common in patients with diabetes, high blood pressure, or cardiovascular disease, has led to the hypothesis of a potential adverse effect of ACE inhibitors and AT1-blockers on the risk of COVID-19 and its course.
This was followed by a rapid response from a number of professional societies, emphasizing the clearly confir-med benefits of this treatment and the lack of scientific and clinical evidence do not justify discontinuation or avoidance of these drugs in the context of COVID-19. Over the last two months, several observational studies have consistently confirmed that this treatment does not increase the risk of developing COVID-19 or its more severe course, and some suggest that it may reduce these risks.